Financial Performance - The Joint Corp's Q2 2025 consolidated Adjusted EBITDA increased by 52% compared to Q2 2024[30, 34] - Q2 2025 comp sales increased by 14%[30] - Q2 2025 system-wide sales increased by 26%[30] - The company reported revenue of $133 million for the three months ended June 30, 2025, a 5% increase compared to $126 million for the same period in 2024[34] - Net loss from continuing operations decreased by 42%, from $17 million in Q2 2024 to $10 million in Q2 2025[34] - Consolidated net income was $01 million, a significant improvement from a net loss of $36 million in the same period last year[34] Clinic Network - Franchised clinics now represent 92% of the company's portfolio[32] - The company refranchised 37 clinics[15] - Total clinics open increased from 842 in 2024 to 885 in Q2 2025[33] 2025 Guidance - System-wide sales are projected to be between $530 million and $550 million[40] - Consolidated Adjusted EBITDA is expected to be between $108 million and $118 million[40] - The company anticipates opening 30 to 35 new franchised clinics, excluding the impact of refranchised clinics[40] Liquidity - The company's unrestricted cash balance as of June 30, 2025, was $298 million[36] - The company has access to a $20 million line of credit with JP Morgan Chase, available through February 2027[36, 38]

Core Viewpoint - Egide Group has updated its 2024 financial statements following audit work, resulting in a restatement of the financial results under French GAAP instead of IFRS, with notable changes in revenue and net results [1][2][3]. Financial Results Summary - The updated 2024 revenue for Egide Group is €30.01 million, a decrease from the previously published €30.04 million, and down from €36.71 million in 2023 [3][4]. - The EBITDA (gross) for 2024 is reported at -€0.44 million, an improvement from -€0.49 million in the previous publication and -€1.02 million in 2023 [4]. - The operating result is -€2.02 million, slightly worse than the previously reported -€1.95 million, but an improvement from -€2.74 million in 2023 [4]. - The net result for the group is -€2.38 million, an improvement from -€2.48 million previously reported and -€3.07 million in 2023 [4]. Adjustments and Variances - Revenue adjustments include a decrease of €0.03 million for Egide SA due to deferred revenue adjustments [5][13]. - Personnel costs decreased by €0.15 million, primarily at Egide USA, from €3.9 million to €3.8 million [5][13]. - The exceptional result improved by €0.14 million, attributed to changes in the share of subsidies recognized in the income statement [8]. Auditor's Position - The statutory auditors have expressed reservations regarding the updated 2024 financial statements, leading to an inability to certify them [15]. - The main areas of uncertainty involve the availability of the 2024 annual financial report, which is scheduled for publication on June 30, 2025 [15][16]. Financial Calendar - The 2024 Annual Financial Report will be published on June 30, 2025, after the French market closure [17]. - Other key dates include the 2025 HY Revenue on July 30, 2025, and the 2025 HY Results on October 20, 2025 [17].